# Indivior Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Indivior Pharmaceuticals, Inc.). ## Overview Indivior Pharmaceuticals, Inc. develops and commercializes treatments for opioid use disorder, with a portfolio centered on long-acting injectable and transmucosal buprenorphine products. The company is headquartered in Richmond, Virginia and sells primarily in the U.S., with a smaller international footprint in Canada, Australia, France, Germany and selected other markets. ## Products & services • SUBLOCADE monthly buprenorphine injection for OUD • SUBOXONE Film for opioid use disorder maintenance • OPVEE opioid overdose reversal product • SUBUTEX Prolonged Release in select non-U.S. markets • Commercial support, reimbursement and medical affairs services - **OUD injectable therapy** (64%) — Long-acting injectable medication used to treat opioid use disorder, anchored by SUBLOCADE. - **OUD transmucosal therapy** (28%) — Sublingual buprenorphine/naloxone film sold mainly in the U.S. through pharmacy channels. - **Rest of World legacy and newer products** (7%) — International sales of SUBLOCADE, SUBUTEX Prolonged Release and legacy tablet products. - **Overdose reversal and other products** (1%) — OPVEE and smaller product lines that are being de-emphasized or supported selectively. - SUBLOCADE monthly extended-release buprenorphine injection - SUBOXONE Film buprenorphine/naloxone sublingual film - OPVEE opioid overdose reversal product - SUBUTEX Prolonged Release in Rest of World markets - Reimbursement support, medical affairs and market access services ## Customers Indivior sells mainly into the U.S. healthcare system, where wholesalers, specialty pharmacies and distributors purchase products and then supply pharmacies, hospitals, federal and state entities, and other care settings. The end users are patients being treated for opioid use disorder, while prescribers, health systems and payors influence access, reimbursement and adoption. A few large wholesale customers account for a significant share of revenue, especially for SUBOXONE Film, while specialty pharmacies and distributors are increasingly important as SUBLOCADE grows. - **U.S. wholesale pharmaceutical distributors** (primary) — Buy SUBOXONE Film and other products for downstream pharmacy and institutional distribution; they are critical because they represent a concentrated share of revenue. - **Specialty pharmacies and specialty distributors** (primary) — Purchase and dispense SUBLOCADE under REMS controls, supporting growth as the product shifts toward broader use. - **Healthcare providers and treatment centers** (primary) — Prescribers and organized health systems choose the therapy based on efficacy, access and administration convenience. - **Government and public payors** (secondary) — Medicaid, federal programs and 340B-related channels buy or reimburse products and strongly influence net pricing. - **International wholesalers and pharmacies** (secondary) — Buy products in Canada, Australia, France and Germany, with additional markets being exited or reduced. - Wholesale pharmaceutical companies that buy for U.S. distribution - Specialty pharmacies and specialty distributors for SUBLOCADE - Hospitals, pharmacies and health systems serving OUD patients - Federal and state entities through government purchasing channels - Patients and prescribers who drive demand through treatment adoption ## Geography The U.S. is Indivior’s core market and accounted for 85% of net revenue in 2025, with the balance coming from Rest of World. International sales are concentrated in Canada, Australia, France and Germany, while the company has announced plans to exit several smaller non-U.S. markets including the U.K., Ireland, Sweden, Israel, Finland and Italy. Manufacturing and supply also matter geographically, including the Fine Chemicals Plant in Hull, U.K. and the Raleigh Manufacturing Facility in the U.S. - **United States** (85%) — Core market based on country where sale originates - **Rest of World** (15%) — Residual international revenue pool - U.S. generated 85% of 2025 net revenue and is the main profit pool - Rest of World contributed 15% of 2025 net revenue - Core non-U.S. markets include Canada, Australia, France and Germany - Plans to exit several smaller markets reduce international complexity - Raleigh and Hull facilities are important to supply and manufacturing ## Strategy Indivior’s current strategy is to concentrate resources on its highest-value OUD therapies, especially SUBLOCADE, while simplifying the organization through the Indivior Action Agenda. The company is also rationalizing its Rest of World footprint by exiting lower-priority markets and reducing support for OPVEE, which should lower complexity and operating expense. At the same time, it is investing in manufacturing capacity and maintaining compliance-heavy distribution systems that are central to its regulated business model. - **Grow SUBLOCADE in the U.S.** (short-term) — It is the main growth engine and offsets declines in legacy products. - **Simplify the operating model** (short-term) — Lower overhead and a leaner structure should improve execution and margins. - **Rationalize international markets** (medium-term) — Concentrating on higher-return countries reduces complexity and execution risk. - **Protect supply and compliance capabilities** (medium-term) — Controlled-substance products require reliable manufacturing, REMS and distribution controls. - Scale SUBLOCADE and defend its position in OUD treatment - Simplify the organization through the Indivior Action Agenda - Exit lower-priority Rest of World markets to focus resources - Reduce support for OPVEE while preserving distribution obligations - Expand Raleigh manufacturing capacity to support supply ## Risks Indivior’s business is exposed to concentration in SUBLOCADE and to a highly regulated controlled-substance environment, where manufacturing, REMS compliance and payor access can materially affect sales. It also faces pricing pressure from generic competition, government reimbursement risk, litigation and scrutiny of patient assistance programs, all of which can compress net revenue. Internationally, currency and market-exit execution add further volatility to an already concentrated portfolio. - **Dependence on SUBLOCADE** [high] — A large share of revenue comes from one product, so any slowdown in adoption, pricing or supply would materially affect results. - **Generic and competitive pressure on SUBOXONE Film** [high] — Competition has already reduced category share and pricing, lowering revenue from the legacy oral product. - **Regulatory and REMS compliance** [high] — Products are controlled substances and require certified distribution and strict manufacturing compliance. - **Reimbursement and Medicaid pricing pressure** [high] — Rebates, discounts, best-price rules and payor negotiations directly reduce net revenue. - **Litigation and enforcement scrutiny** [medium] — The company operates in a sector with elevated legal and regulatory exposure, including patient assistance program scrutiny. - **Foreign exchange and market exits** [medium] — International revenue is smaller but exposed to currency swings and execution risk as markets are exited. - Heavy dependence on SUBLOCADE creates product concentration risk - Generic competition pressures SUBOXONE Film pricing and share - REMS, cGMP and controlled-substance rules can disrupt supply - Medicaid, rebates and payor pressure reduce net revenue realization - Litigation and patient assistance scrutiny can create cash and legal risk ## Accounting The most important accounting judgments are the estimates for rebates, discounts, returns and prompt-pay deductions, which are recorded as reductions of gross revenue and can move materially with product mix and channel volume. Indivior also carries significant restructuring, litigation and contractual obligation costs, while manufacturing and market-exit actions can create asset impairments and termination charges. Because the business sells through government and specialty channels, net revenue can differ meaningfully from gross sales depending on Medicaid, commercial rebates and other deductions. - **Revenue deductions and rebate reserves** — Accrued rebates and product returns were $585 million at year-end 2025 - **Gross-to-net adjustments** — Can change reported revenue growth versus underlying demand - **Restructuring and impairment charges** — 2025 charges were significant and expected to lower 2026 operating expense - **Litigation and contractual obligations** — Can affect liabilities, cash flow and comparability across periods - Revenue is reported net of rebates, discounts, returns and chargebacks - Accrued rebates and returns are highly judgmental and product-mix sensitive - REMS and specialty-channel sales affect timing and channel deductions - Restructuring, impairments and termination costs can be material - Litigation settlements and contingent obligations affect cash and earnings --- *Last updated: 2026-04-28T20:17:14.407167+00:00*